Patents by Inventor Urs Beat Hagemann

Urs Beat Hagemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220125960
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being a PD-1/PD-L1 inhibitor, and component B being a targeted thorium conjugate. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 28, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer AS
    Inventors: Urs Beat HAGEMANN, Pascale LEJEUNE, Jenny KARLSSON, Alan CUTHBERTSON, Stefanie HAMMER
  • Publication number: 20220118123
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 21, 2022
    Applicants: Bayer Aktiengesellschaft, BAYER AS
    Inventors: Stefanie HAMMER, Urs Beat HAGEMANN, Bernard HAENDLER, Pascale LEJEUNE, Sabine ZITZMANN-KOLBE, Christoph SCHATZ, Jenny KARLSSON
  • Publication number: 20210054099
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: April 24, 2020
    Publication date: February 25, 2021
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Patent number: 10683367
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 16, 2020
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Publication number: 20190119402
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: July 13, 2018
    Publication date: April 25, 2019
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Patent number: 10266599
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 23, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Urs Beat Hagemann, Remko Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Patent number: 10047165
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Publication number: 20170088632
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: September 13, 2016
    Publication date: March 30, 2017
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Publication number: 20170051067
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: November 11, 2016
    Publication date: February 23, 2017
    Applicant: Cancer Research Technology Limited
    Inventors: Urs Beat Hagemann, Remko Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Patent number: 9475885
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: October 25, 2016
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Patent number: 9458238
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: October 4, 2016
    Assignee: Cancer Research Technology Limited
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Publication number: 20160002349
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: March 17, 2015
    Publication date: January 7, 2016
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Patent number: 9011860
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: April 21, 2015
    Assignee: Omeros Corporation
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Publication number: 20150104831
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Applicant: AFFITECH RESEARCH AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Patent number: 8969253
    Abstract: The present invention relates to a method for screening phage display libraries against each other. In particular, the invention relates to a method for screening at least two phage display libraries against each other to identify and/or select one or more interacting binding partners or binding molecules making up such interacting binding partners. Kits providing two bispecific phage display libraries are also provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: March 3, 2015
    Assignee: Nextera AS
    Inventors: Herald Reiersen, Geir Age Loset, Urs Beat Hagemann
  • Patent number: 8895007
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: November 25, 2014
    Assignee: Affitech Research AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Publication number: 20120282263
    Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Application
    Filed: May 4, 2012
    Publication date: November 8, 2012
    Applicant: OMEROS CORPORATION
    Inventors: Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
  • Publication number: 20120164161
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 28, 2012
    Applicant: AFFITECH RESEARCH AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Publication number: 20110318269
    Abstract: The present invention relates to a method for screening phage display libraries against each other. In particular, the invention relates to a method for screening at least two phage display libraries against each other to identify and/or select one or more interacting binding partners or binding molecules making up such interacting binding partners. Kits providing two bispecific phage display libraries are also provided.
    Type: Application
    Filed: February 26, 2010
    Publication date: December 29, 2011
    Applicant: NEXTERA AS
    Inventors: Herald Reiersen, Geir Age Loset, Urs Beat Hagemann